berdazimer
Zelsuvmi
Pharmaceutical company: LNHC, Inc.
Pharmacologic classification: Nitric oxide-releasing agent
Therapeutic classification: Antiviral
AVAILABLE FORMS
Gel: 10.3% berdazimer supplied as two tubes (Tube A contains 14 g berdazimer and Tube B contains 17 g hydrogel)
INDICATIONS AND DOSAGES
Molluscum contagiosum
Adults and children age 1 and older: Mix 0.5-mL gel from Tube A and 0.5-mL gel from Tube B on the manufacturer-provided dosing guide. Immediately apply as an even, thin layer once daily to each molluscum contagiosum lesion for up to 12 weeks.
CONTRAINDICATIONS AND CAUTIONS
- Application site reactions, including allergic contact dermatitis, have occurred.
- Safety and effectiveness in children younger than 1 year haven't been established.
- Dialyzable drug: Unknown
PREGNANCY-LACTATION-REPRODUCTION
- There are no adequate studies during pregnancy. Fetal risk is unknown.
- It isn't known whether drug appears in human milk. Before use during breastfeeding, consider the patient's need for therapy and the potential effects on the infant.
INTERACTIONS
None reported by the manufacturer.
ADVERSE REACTIONS
CNS: fever.
GI: vomiting.
Respiratory: upper respiratory infection.
Skin: application site pain, erythema, stinging, burning, pruritis, exfoliation, dermatitis, swelling, erosion, discoloration, vesicles, irritation, infection.
Reactions in bold italics are life-threatening.
Released: April 2024
Nursing Drug Handbook
© 2024 Wolters Kluwer